Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 known ✓ | O43570 | 1/20 | 0.39 |
| ▸ | CA1 known ✓ | P00915 | 1/20 | 0.39 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.39 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.34 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL10934871 | 0.96 | CA12 (0.44) | FPR2NOD1CHRM1AKR1A1CHRM3 | |
| SCHEMBL10933041 | 0.84 | CA12 (0.47) | NOD1CA12CA1CA2CA9 | |
| SCHEMBL12291691 | 0.82 | FPR2 (0.46) | FPR2NOD1CHRM1AKR1A1CHRM3 | |
| SCHEMBL7641648 | 0.80 | FPR2 (0.45) | FPR2NOD1CHRM1AKR1A1CHRM3 | |
| Lithium Ion SCHEMBL10935110 | 0.80 | CA12 (0.47) | NOD1CA12CA1CA2CA9 | |
| SCHEMBL10146967 | 0.77 | FPR2 (0.49) | FPR2NOD1CHRM1AKR1A1CHRM3 | |
| SCHEMBL28688352 | 0.77 | FPR2 (0.43) | FPR2NOD1CHRM1AKR1A1CHRM3 | |
| SCHEMBL28676083 | 0.77 | FPR2 (0.43) | FPR2NOD1CHRM1AKR1A1CHRM3 | |
| SCHEMBL28688354 | 0.77 | FPR2 (0.40) | FPR2NOD1CHRM1AKR1A1CHRM3 | |
| SCHEMBL16748603 | 0.75 | MAPT (0.59) | FPR2NOD1CHRM1AKR1A1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4554108-A | Alkali carboxyalkyl dithiocarbamates and use as ore flotation reagents | PHILLIPS PETROLEUM COMPANY (US) | 1985-11-19 | — | — | US | claimed |
| CN-110035829-B | Depressant composition and method for depressing gangue sulfide minerals during flotation of sulfide ores | 塞特工业公司 | 2021-12-24 | — | — | CN | disclosed |
| US-10710099-B2 | Compositions and methods for selective separation of minerals from sulfide ores | CYTEC INDUSTRIES INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190336984-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE SEPARATION OF MINERALS FROM SULFIDE ORES | CYTEC INDUSTRIES INC. (US) | 2019-11-07 | — | — | US | disclosed |
| US-10369577-B2 | Compositions and methods for selective separation of minerals from sulfide ores | CYTEC INDUSTRIES INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180099293-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE SEPARATION OF MINERALS FROM SULFIDE ORES | CYTEC INDUSTRIES INC. | 2018-04-12 | — | — | US | disclosed |
| US-4554068-A | DITHIOCARBAMATES AS SUPPRESSANTS | PHILLIPS PETROLEUM COMPANY (US) | 1985-11-19 | — | — | US | disclosed |
| US-4554108-A | Alkali carboxyalkyl dithiocarbamates and use as ore flotation reagents | PHILLIPS PETROLEUM COMPANY (US) | 1985-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10369577-B2 | Compositions and methods for selective separation of minerals from sulfide ores | TST, CTH, PFAS | CA12 506/4885CA1 67/4885CA2 46/4885 |
| US-20190336984-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE SEPARATION OF MINERALS FROM SULFIDE ORES | TST, CTH, PFAS | CA12 506/4885CA1 67/4885CA2 46/4885 |
| US-10710099-B2 | Compositions and methods for selective separation of minerals from sulfide ores | TST, CTH, PFAS | CA12 506/4885CA1 67/4885CA2 46/4885 |
| US-20180099293-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE SEPARATION OF MINERALS FROM SULFIDE ORES | TST, CTH, PFAS | CA12 506/4885CA1 67/4885CA2 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.